Vis enkel innførsel

dc.contributor.authorHofsø, Dag
dc.contributor.authorFatima, Farhat
dc.contributor.authorBorgeraas, Heidi
dc.contributor.authorBirkeland, Kåre I.
dc.contributor.authorGulseth, Hanne Løvdal
dc.contributor.authorHertel, Jens Kristoffer
dc.contributor.authorJohnson, Line Kristin
dc.contributor.authorLindberg, Morten
dc.contributor.authorNordstrand, Njord
dc.contributor.authorSmåstuen, Milada Cvancarova
dc.contributor.authorStefanovski, Darko
dc.contributor.authorSvanevik, Marius
dc.contributor.authorValderhaug, Tone Gretland
dc.contributor.authorSandbu, Rune
dc.contributor.authorHjelmesæth, Jøran
dc.date.accessioned2020-01-18T10:20:58Z
dc.date.accessioned2020-04-08T09:23:42Z
dc.date.available2020-01-18T10:20:58Z
dc.date.available2020-04-08T09:23:42Z
dc.date.issued2019-10-30
dc.identifier.citationHofsø D, Fatima F, Borgeraas H, Birkeland KI, Gulseth HL, Hertel J, Johnson LK, Lindberg M, Nordstrand N, Småstuen MC, Stefanovski D, Svanevik M, Valderhaug TG, Sandbu R, Hjelmesæth J. Gastric bypass versus sleeve gastrectomy in patients with type 2 diabetes (Oseberg): a single-centre, triple-blind, randomised controlled trial. The Lancet Diabetes and Endocrinology. 2019;7(12):912-924en
dc.identifier.issn2213-8587
dc.identifier.issn2213-8587
dc.identifier.issn2213-8595
dc.identifier.urihttps://hdl.handle.net/10642/8400
dc.description.abstractBackground: The comparative effectiveness of various bariatric procedures on remission of type 2 diabetes remains debated. We aimed to compare the two most commonly used procedures, hypothesising higher remission rates of diabetes after gastric bypass than after sleeve gastrectomy. Methods: The Oseberg study is an ongoing triple-blind, randomised, single-centre trial taking place at Vestfold Hospital Trust, Norway. Adult patients with type 2 diabetes and obesity were randomly assigned (1:1) to receive either gastric bypass or sleeve gastrectomy. Randomisation was performed with a computerised random number generator using block sizes of 10. Treatment allocation was concealed using sealed opaque envelopes, and was masked from participants, study personnel and outcome assessors. Primary outcomes were, first, the proportion of participants with complete remission of diabetes; glycated haemoglobin 6·0% (42 mmol/mol) or less with no diabetes medication, and, second, beta-cell function modelled from an intravenous glucose tolerance test at one year. Analyses were performed according to intention-to-treat and per-protocol principles. The trial is registered at ClinicalTrials.gov with identifier: NCT01778738. Findings: Between January 28, 2013 and February 4, 2018, 109 patients were randomly assigned to gastric bypass (n=54) or sleeve gastrectomy (n=55), with a total of 107 (98%) patients completing 1-year follow-up. Remission of diabetes occurred in 40/53 patients (75%) in the gastric bypass-group and 26/54 patients (48%) in the sleeve gastrectomy-group; risk ratio 1·57, 95% CI 1·14–2·15; p=0·0036. Beta-cell function increased 6- to 7-fold from baseline, with no differences between groups. The number of early and late complications after gastric bypass and sleeve gastrectomy were 10 versus 8 and 17 versus 22, respectively. Interpretation: Gastric bypass being found to be superior to sleeve gastrectomy for remission of type 2 diabetes might have important individual and societal implications, including the potential to improve diabetes care and reduce related societal costs.en
dc.description.sponsorshipThe study is organised and financed by the Vestfold Hospital Trust and the Morbid Obesity Centre. All employees receive a salary from their respective departments. FF has received a grant from the South-Eastern Norway Regional Health Authority.en
dc.language.isoenen
dc.publisherElsevieren
dc.publisherLanceten
dc.relation.ispartofseriesThe Lancet Diabetes and Endocrinology;Volume 7, ISSUE 12
dc.rights© 2019. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/en
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectGastric bypassesen
dc.subjectBariatric proceduresen
dc.subjectType 2 diabetesen
dc.subjectSleeve gastrectomyen
dc.subjectRandomised controlled trialsen
dc.titleGastric bypass versus sleeve gastrectomy in patients with type 2 diabetes (Oseberg): a single-centre, triple-blind, randomised controlled trialen
dc.typeJournal articleen
dc.typePeer revieweden
dc.date.updated2020-01-18T10:20:58Z
dc.description.versionacceptedVersionen
dc.identifier.doihttps://dx.doi.org/10.1016/S2213-8587(19)30344-4
dc.identifier.cristin1746114
dc.source.journalThe Lancet Diabetes and Endocrinology


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

© 2019. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
Med mindre annet er angitt, så er denne innførselen lisensiert som © 2019. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/